Contact us if you would like more information about IntegraGen and our efforts.
19 April 2021 Bernard Courtieu, CEO of IntegraGen said: “2020 was an exceptional year for IntegraGen in several ways. Commercial activities achieved double-digit growth, results were close to breakeven for the second consecutive year, and the company’s cash position was strengthened, despite the considerable impact of the health crisis.” 15 March 2021 As provider of the whole genome sequencing, IntegraGen is proud of sharing this new publication. Urinary tract infections (UTIs) are caused by an uropathogenic strain of Escherichia coli that produce colibactin, a bacterial genotoxin. In the study (…) » 03 March 2021 As provider of the bulk and single-cell RNA-seq libraries and sequencing, IntegraGen is proud of sharing this new publication. Duchenne Muscular Dystrophy (DMD) is a rare disease characterized by early muscular damages. The (…) » 12 January 2021 IntegraGen announced today its unaudited business figures for the year 2020. 09 October 2020 Analysis of circulating tumor DNA (ctDNA) offers great opportunities for cancer research and patient care. There are multiple applications and benefits associated with studying ctDNA including the ability to identify tumor heterogeneity and the detection of somatic mutations unidentified following (…) » 18 September 2020 IntegraGen has announced today its financial results for the first half of 2020 with the accounts having been reviewed by the Board of Directors on 17 September 2020. Company posts positive operating performance (EBITDA) for the second consecutive semester, supported by revenue growth (+5%) and confirms (…) » 16 September 2020 This press release was prepared and distributed by OncoDNA S.A. in accordance with the provisions of Articles 231-27 1 ° and 2 ° and 231-28 of the general regulations of the Autorité des marchés financiers (the “AMF”). 01 September 2020 IntegraGen’s Combined General Assembly for 2020 will be held on September 17, 2020 at 2 p.m. at the company’s headquarters which is located at Génopole Campus 1,Genavenir 8, Porte 840, 5 rue Henri Desbruères – 91000 Evry, France 09 July 2020 Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN to acquire all outstanding shares at a price of 2.20€ per share. This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of (…) » 09 July 2020 IntegraGen announced unaudited sales for the first half of 2020 were 4,706 k€, an increase of 13% compared to the first half of 2019 and 15% on a like-for-like basis taking into account the sale of the company’s diagnostic business at the start of 2020. The growth in sales (…) » IntegraGen reports 2020 annual results: 10% growth in revenue from current operations and achievement of breakeven operating profits
Potential implication of urinary tract infections (UTIs) in bladder cancer development
Uropathogenic E.coli induces DNA damage in the bladder
New discoveries in DMD development open new perspectives for the disease diagnosis and therapeutics
Myogenesis modelled by human pluripotent stem cells: a multi-omic study of Duchenne myopathy early onset
IntegraGen reports 2020 revenue of €9.0 million, an increase of +10%, and a cash position of €5.0 million as of December 31, 2020
Technical Brief: Low-Pass Whole Genome Sequencing – Getting more from less
LP-WGS analysis of liquid biopsies (ctDNA) for oncology applications Background
IntegraGen Reports Results for 1st Half of 2020
COMMUNIQUE PROVIDING THE INFORMATION NOTE AND THE DOCUMENT “OTHER INFORMATION RELATING TO CHARACTERISTICS, IN PARTICULAR LEGAL, FINANCIAL AND ACCOUNTING” OF THE COMPANY ONCODNA S.A.
COMBINED GENERAL ASSEMBLY
Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN
IntegraGen reports sales of €4.7 million in the first half of 2020, up 13%, and cash position of €5.8 million
